Scholarlink

Purpose <p>Renal function significantly influences the pharmacokinetics of imipenem/cilastatin/relebactam (IMI/REL). The standardized single-dose packaging commonly leads to considerable drug wastage when the medication is administered to patients with renal impairment. This investigation aimed to develop and assess alternative dosage regimens that optimize drug utilization and minimize waste.</p> Methods <p>Through Monte Carlo simulations, we evaluated alternative regimens involving extended dosage intervals and prolonged infusion times across patients with various levels of renal impairment. We assessed probabilities of target attainment (PTA) against established pharmacokinetic/pharmacodynamic (PK/PD) targets and minimum inhibitory concentration (MIC) breakpoints, and evaluated the risk of drug overexposure. Additionally, we compared the alternative dosage regimens with standard regimens in terms of dose wastage and cost savings.</p> Results <p>The findings suggest that administering full doses of IMI/REL every 8–12&#xa0;h with prolonged infusion achieves satisfactory PTAs without significant overexposure risks. These alternative regimens are anticipated to reduce direct medical costs by $335.84 to $671.68 daily compared to standard dosages.</p> Conclusion <p>Alternative dosing regimens for IMI/REL in patients with renal impairment can optimize drug utilization, minimize waste, and provide significant cost savings. However, further clinical studies are necessary to validate the effectiveness and safety of these regimens.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Cost-minimizing alternative dosage regimens of imipenem/cilastatin/relebactam for patients with renal impairment: a pharmacokinetic/pharmacodynamic simulation study

  • 期刊论文

  • 发表日期：

    2026年1月2日

查看全文
  • Xiaoping Shi,
  • Donghui Lao,
  • Qing Xu,
  • Xiaoyu Li,
  • Bijue Liu,
  • Qingfeng He,
  • Xiao Zhu,
  • Qianzhou Lv

摘要

Purpose

Renal function significantly influences the pharmacokinetics of imipenem/cilastatin/relebactam (IMI/REL). The standardized single-dose packaging commonly leads to considerable drug wastage when the medication is administered to patients with renal impairment. This investigation aimed to develop and assess alternative dosage regimens that optimize drug utilization and minimize waste.

Methods

Through Monte Carlo simulations, we evaluated alternative regimens involving extended dosage intervals and prolonged infusion times across patients with various levels of renal impairment. We assessed probabilities of target attainment (PTA) against established pharmacokinetic/pharmacodynamic (PK/PD) targets and minimum inhibitory concentration (MIC) breakpoints, and evaluated the risk of drug overexposure. Additionally, we compared the alternative dosage regimens with standard regimens in terms of dose wastage and cost savings.

Results

The findings suggest that administering full doses of IMI/REL every 8–12 h with prolonged infusion achieves satisfactory PTAs without significant overexposure risks. These alternative regimens are anticipated to reduce direct medical costs by $335.84 to $671.68 daily compared to standard dosages.

Conclusion

Alternative dosing regimens for IMI/REL in patients with renal impairment can optimize drug utilization, minimize waste, and provide significant cost savings. However, further clinical studies are necessary to validate the effectiveness and safety of these regimens.